Alexion Pharmaceuticals shuttered the company’s oral small molecule Factor D inhibitor program for a rare kidney disease following disappointing clinical data.

A review of recently published scientific studies includes a look at the potential of using flu and pneumonia vaccines to decrease the risk of developing Alzheimer’s disease.

Results of a pivotal phase III study of Supernus Pharmaceuticals’ SPN-812 (viloxazine extended-release capsules) were published in the journal Clinical Therapeutics.

AbbVie’s investigational migraine drug atogepant significantly reduced mean monthly migraine days across a 12-week course of treatment.

Boehringer Ingelheim and Eli Lilly announced that the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, met the primary endpoint.

Johnson & Johnson kicked off U.S. human safety trials for a Covid-19 vaccine after releasing details of a study in monkeys that showed the company’s best-performing vaccine candidate offered strong protection in a single dose.

British drugmaker AstraZeneca topped second-quarter sales and profit estimates and backed the company’s 2020 forecasts, helped by strong sales in lockdowns of a diverse product range that includes a potential coronavirus vaccine.

Brussels, Belgium-based UCB entered into a global licensing deal with Roche and Genentech to develop and commercialize UCB0107 in Alzheimer’s disease.

Bristol Myers Squibb and bluebird bio announced the submission of their Biologics License Application (BLA) to the U.S. Food and Drug Administration for idecabtagene vicleucel for the treatment of adult patients with relapsed and refractory multiple myeloma.

Three months after joining forces to develop an adjuvanted vaccine for Covid-19, Sanofi and GlaxoSmithKline reached an agreement with the U.K. government to provide up to 60 million doses of the preventative medication.